Faslodex Uses

Faslodex uses are primarily concerned with the treatment of breast cancer in postmenopausal women. The medicine works by blocking the action of estrogen receptors in the body, which lowers the production of this hormone and helps decrease the cancer's growth. Faslodex is not approved for use in children, adolescents, or men. Off-label Faslodex uses can include the treatment of breast cancer in premenopausal women.

Faslodex Uses: An Overview

Faslodex® (fulvestrant) is a prescription medication used to treat breast cancer in postmenopausal women. Specifically, the drug has been licensed to treat postmenopausal women with hormone receptor-positive breast cancer that has worsened while taking other breast cancer hormone treatments.

Understanding Breast Cancer

Women in the United States get breast cancer more than any other type of cancer, except for skin cancer. Each year, more than 211,000 American women learn that they have the disease. Most causes of breast cancer are not known. In 5 to 10 percent of these cases, there is a hereditary component. Common breast cancer symptoms include:
  • A lump or thickening in or near the breast or in the underarm area
  • A change in how the breast or nipple feels
  • Nipple tenderness
  • A change in how the breast or nipple looks
  • A change in the size or shape of the breast
  • A nipple turned inward into the breast
  • Nipple discharge (fluid).
In general, breast cancer treatment options can include:
The best treatments can vary, depending on the stage of the breast cancer (see Breast Cancer Treatment by Stage).
5 Common Relationship Mistakes for Adults With ADHD

Faslodex Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2020 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.